Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

30 trials with published results (29%)

Research Maturity

77 completed trials (74% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.9%

3 terminated out of 104 trials

Success Rate

96.3%

+9.7% vs benchmark

Late-Stage Pipeline

54%

56 trials in Phase 3/4

Results Transparency

39%

30 of 77 completed with results

Key Signals

30 with results96% success

Data Visualizations

Phase Distribution

86Total
Not Applicable (12)
P 1 (4)
P 2 (14)
P 3 (35)
P 4 (21)

Trial Status

Completed77
Unknown14
Not Yet Recruiting5
Terminated3
Recruiting3
Active Not Recruiting1

Trial Success Rate

96.3%

Benchmark: 86.5%

Based on 77 completed trials

Clinical Trials (104)

Showing 20 of 20 trials
NCT02325310Phase 4CompletedPrimary

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR

NCT07406360Phase 3Not Yet RecruitingPrimary

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT07338851Not Yet Recruiting

the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

NCT06331702Phase 4Completed

Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

NCT07112846Not Yet Recruiting

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT03071575Phase 4CompletedPrimary

Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age

NCT05630846Phase 2Completed

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05860920Not Yet RecruitingPrimary

Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in Senegal

NCT06456788CompletedPrimary

Barriers and Facilitators to MMR Vaccination Among Healthcare Workers

NCT06218368Not ApplicableActive Not RecruitingPrimary

A Tool Kit to Improve Vaccine Confidence in the Philippines

NCT06815835Phase 3Not Yet RecruitingPrimary

Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

NCT05614791CompletedPrimary

Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience

NCT06667206Phase 2RecruitingPrimary

Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings

NCT04899765Phase 4Recruiting

Measles and BCG Vaccines for Mother and Child

NCT05894395Phase 3Unknown

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination

NCT05771779Phase 3Unknown

Co-administration Study of OCV, TCV and MR

NCT05952505Phase 4Unknown

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

NCT05592756CompletedPrimary

Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed

NCT05803538Not ApplicableUnknownPrimary

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Scroll to load more

Research Network

Activity Timeline